Wednesday, March 21, 2018

Star ETorque Electric Handpiece System

For the past 5 years or so I have been using electric handpieces almost exclusively.  I had tried them many years ago (almost 20 to be exact) and was less than overwhelmed.  However, the newer generations are simply incredible!  They are high torque, incredibly precise, and amazingly durable.
I will on occasion still pick up an air driven system, but it is a rarity.
The Star ETorque is the latest electric from DentalEZ.  If you are interested in more info, here is the link.  

Tuesday, March 20, 2018

Centers for Disease Control Report: Dental Personnel Treated for Idiopathic Pulmonary Fibrosis at a Tertiary Care Center — Virginia, 2000–2015

In the CDC’s Morbidity and Mortality Weekly Report (MMWR) from March 9, 2018 comes information on a respiratory disease that had a large “cluster” of dentists.  I’m not sure what this means for the profession at this point in time, but it definitely deserves reading at this point in time.
Here is the report:

In April 2016, a Virginia dentist who had recently received a diagnosis of idiopathic pulmonary fibrosis (IPF) and was undergoing treatment at a specialty clinic at a Virginia tertiary care center contacted CDC to report concerns that IPF had been diagnosed in multiple Virginia dentists who had sought treatment at the same specialty clinic. IPF is a chronic, progressive lung disease of unknown cause and associated with a poor prognosis (1). Although IPF has been associated with certain occupations (2), no published data exist regarding IPF in dentists. The medical records for all 894 patients treated for IPF at the Virginia tertiary care center during September 1996–June 2017 were reviewed for evidence that the patient had worked as a dentist, dental hygienist, or dental technician; among these patients, eight (0.9%) were identified as dentists and one (0.1%) as a dental technician, and each had sought treatment during 2000–2015. Seven of these nine patients had died. A questionnaire was administered to one of the living patients, who reported polishing dental appliances and preparing amalgams and impressions without respiratory protection. Substances used during these tasks contained silica, polyvinyl siloxane, alginate, and other compounds with known or potential respiratory toxicity. Although no clear etiologies for this cluster exist, occupational exposures possibly contributed. This cluster of IPF cases reinforces the need to understand further the unique occupational exposures of dental personnel and the association between these exposures and the risk for developing IPF so that appropriate strategies can be developed for the prevention of potentially harmful exposures.

IPF is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IPF is associated with histopathologic and radiologic patterns of usual interstitial pneumonia in the absence of other known causes of interstitial lung disease (1) and is characterized by unexplained slowly progressive dyspnea that can be accompanied by a nonproductive cough (2). Available treatment options for IPF include pharmacotherapy (i.e., pirfenidone and nintedanib) and lung transplantation (2). The estimated median survival after diagnosis is 3–5 years (2). Although the etiology of IPF is unknown, exposures that have been suggested as contributing factors include viral infections, cigarette smoking, and occupations where exposure to dust, wood dust, and metal dust are common (2). In the United States, on the basis of the case definitions used by separate studies to analyze data collected during 1988–2005, the estimated annual incidence of IPF varied from 6.8 to 17.4 per 100,000 population, and the estimated prevalence varied from 14.0 to 63.0 per 100,000 population (3) and increased with increasing age (2). No published data could be found regarding dental personnel and IPF.

In June 2017, the electronic medical records of all 894 patients with a diagnosis of IPF treated at the Virginia specialty clinic during September 1996–June 2017 were reviewed to identify patients having the occupation of dentist, dental hygienist, or dental technician. Available electronic medical records of patients identified as having one of these occupations were reviewed, pertinent data were abstracted, and an attempt was made to interview living patients to ascertain symptoms and occupational and nonoccupational exposures, after obtaining informed consent. This study received approval from the Inova Fairfax Hospital Institutional Review Board.

Among 894 patients treated for IPF at the tertiary care center, nine (1%) were identified as dental personnel, including eight dentists and one dental technician. All patients were male and were treated during 2000–2015. Five were white, one was black, and the race of three was unknown. At the time of pulmonary consultation, the median patient age was 64 years (range = 49–81 years) (Table). States of residence included Virginia (five), Maryland (three), and Georgia (one). Seven of the nine patients had died; among these, the median survival time from consultation was 3 years (range = 1–7 years). Among eight patients tested at the time of pulmonary consultation, pulmonary function tests demonstrated three patients had normal spirometry, two of whom also had documented normal lung volumes, and five patients had restrictive spirometry and low lung volumes, interpreted as lung restriction. Each of the five patients with restriction had low predicted values for diffusing capacity of the lungs for carbon monoxide (DLCO) (median = 47% [range = 19%–55%]). Pulmonary function test results were not available for one patient. One of the living patients who did not complete an interview underwent a lung transplant 3 years after diagnosis. No tissue specimens were available for analysis.

Three patients were former smokers, one had never smoked, and smoking history was unknown for five (Table). A telephone interview was conducted with the patient who had contacted CDC; it was not possible to complete an interview with the other living patient. The interviewed patient, who had never smoked, reported not wearing a National Institute for Occupational Safety and Health-certified respirator during dental activities throughout his 40-year dental practice; he wore a surgical mask for the last 20 years of his dental practice. He reported performing polishing of dental appliances, preparing amalgams and impressions, and developing x-rays using film developing solutions. He also reported work-related exposure to dust while working as a street sweeper for 3 months before entering dental school and environmental exposure to dust from coral beaches for approximately 15 years while intermittently visiting the Caribbean region as a practicing dentist.
During September 1996–June 2017, nine (1%) of 894 patients treated for IPF at a single tertiary care center in Virginia were identified as dental personnel. Each patient presented for care during 2000–2015. Seven of the patients had died. This is the first known described cluster of IPF occurring among dental personnel. Although no clear etiology exists for this cluster, it is possible that occupational exposures contributed to the development of IPF.

During 2016, dentists accounted for an estimated 0.038% of U.S. residents (4), yet represented 0.893% of patients undergoing treatment for IPF at one tertiary care center, nearly a 23-fold difference. Dental personnel are exposed to infectious agents, chemicals, airborne particulates, ionizing radiation, and other potentially hazardous materials (5). Inhalational exposures experienced by dentists likely increase their risk for certain work-related respiratory diseases. For example, cases of dental technicians with pneumoconiosis, a restrictive occupational lung disease resulting from inhalation of dust, have been identified after exposure to either silica or cobalt-chromium-molybdenum-based dental prostheses (6,7). A case of pneumoconiosis was identified postmortem in an elderly dentist who died from respiratory failure (8). Examination of lung tissue at autopsy using scanning electron microscopy revealed particles consistent with alginate impression powders used during the dentist’s practice. Nine cases of silicosis were recognized among dental laboratory technicians exposed to crystalline silica in five states during 1994–2000 (9). Asbestos-related lung disease, attributed to manipulating wet asbestos-containing paper during preparation of molds in casting operations, has also been identified in dentists (10). The one living patient in this cluster who was interviewed reported occupational exposures to silica and other materials used in dental practice, but also other work-related and environmental exposures to dust.

IPF has not been previously described among dental personnel. However, a query of the National Occupational Respiratory Mortality System for 4 separate years (1999, 2003, 2004, and 2007) for “other interstitial pulmonary diseases with fibrosis”* (which would include IPF) listed as the underlying or contributing cause of death revealed 35 decedents categorized as having worked in the “office of dentists” and 19 categorized as having the occupation “dentist,” with proportionate mortality ratios of 1.52 (95% confidence interval [CI] = 1.05–2.11) and 1.67 (95% CI = 1.01–2.61), respectively (Respiratory Health Division, CDC, unpublished data, 2017). These findings suggest that a higher rate of IPF might occur among dental personnel than among the general population.

The living patient who was interviewed reported occupational exposures to known respiratory hazards (e.g., silica) yet did not wear National Institute for Occupational Safety and Health-certified respiratory protection. It is possible other patients in this case series had similar experiences. Dental personnel who perform tasks that result in occupational exposures to known respiratory hazards should wear adequate respiratory protection if other controls (e.g., improved ventilation) are not practical or effective ( If respiratory protection is used, a written respiratory protection program should be implemented as required by the Occupational Safety and Health Administration Respiratory Protection Standard, including training, fit testing, and maintenance and use requirements (

The findings in this report are subject to at least four limitations. First, in this analysis, only patients undergoing treatment at a single tertiary care center specializing in IPF treatment were identified, which might have led to an overrepresentation of dentists, given their comparatively high socioeconomic status. Conversely, dental personnel in Virginia and the surrounding region undergoing IPF treatment at other facilities during this same time frame were not identified, thereby potentially underrepresenting the magnitude of this cluster. Second, only one patient completed an interview, limiting the ability to explore past occupational exposures. Third, multiple patients had reported exposures that occurred outside of work and that are known risk factors for IPF, including tobacco smoke and dust (2). Finally, no biopsy specimens were available for examination to assess histological commonalities among the patients.

This investigation revealed the first described cluster of dental personnel with diagnosed IPF. The eight dentists identified in this cluster exceeded the number of expected cases, consistent with National Occupational Respiratory Mortality System data regarding IPF mortality and the proportion of U.S. residents who are dentists. Dentists and other dental personnel experience unique occupational exposures, including exposure to infectious organisms, dusts, gases, and fumes. It is possible that occupational exposures contributed to this cluster. After this analysis, another IPF case was diagnosed in a dentist treated at this specialty clinic. Further investigation of the risk for dental personnel and IPF is warranted to develop strategies for prevention of potentially harmful exposures.
John Wood, Respiratory Health Division, National Institute for Occupational Safety and Health, CDC.

Monday, March 19, 2018

Clinical Evaluation of Goby Toothbrush in Progress

Goby all black.png
While strolling the aisles of the Chicago Dental Society’s Annual MidWinter Meeting, I came across a small booth for a company called Goby.
I had heard about Goby and their cool powered toothbrush before, but I had never had a chance to actually get my hands on one.  The folks at the booth were energetic and friendly and they told me a bit about Goby and their mission as a company.
Basically the company believes that a good quality powered toothbrush shouldn’t be a tremendously expensive item.  To that end, they are selling their brushes for $50 to $60 depending on the color.  They have an all black kit (pictured above and *surprise* my personal favorite) and an all pink both for $60 and a white version for $50.
Devices like this are a perfect fit into my ‘wheelhouse’ as they help both dentists and patients while providing great technology.  I haven’t used a manual brush for at least a decade and I would never go back.  We don’t sell brushes in our office, but we are always recommending powered brushes to our patients.  Of course the #1 pushback we receive is the cost of the brush.  Goby caught my eye because it’s a powered brush that the company is making an effort to keep affordable.
On Thursday, my all black Goby arrived!  So, for the next 4 weeks or so, I’m going to be using it and I’ll report back on my experiences.

Thursday, March 15, 2018

Ultradent Announces Special Event: Icons of Dentistry: A Workshop for Women


Last year, my business partner Dr. John Huebner and I were fortunate enough to be part of Ultradent’s Women in Dentistry Meeting.  It was a really great event and in addition to learning a bunch, we also had a really great time.  Needless to say we’re both pretty fired up about this year’s event being held in South Jordan, Utah at Ultradent’s World Headquarters.  All the details are listed below.  If you have the dates available, I highly recommend you attend! 

Here is the announcement from Ultradent:

In honor of International Women’s Day, Ultradent is pleased to announce an upcoming special two-day event, Icons of Dentistry: A Workshop for Women. It is a weekend of networking, socializing, rejuvenation, and education to celebrate women in dentistry. This year’s theme for the workshop will be Compassion.

The Icons of Dentistry: A Workshop for Women event will take place June 22–23, 2018 at Ultradent’s international headquarters in South Jordan, UT. It will feature iconic women in the field of dentistry teaching classes and workshops on everything from work/life balance, practice building and management, esthetic dentistry, lasers, and more. There will also be a special keynote speaker to be announced later this month.

Attendees will be treated to a special dinner in an orchard at the home of Dr. Dan Fischer, founder and CEO of Ultradent, as well as a cocktail social where attendees can mingle with each other and the event’s speakers. Additionally, attendees will be treated to an evening of dinner and drinks at one of Utah’s highest-rated restaurants, Tuscany.

By attending Icons of Dentistry: A Workshop for Women, clinicians will earn 16 continuing education credits. Registration begins March 8, 2018, with 100 spots available. Tickets are $199.

To register for, or learn more about Icons of Dentistry: A Workshop for Women, please call 800.520.6640 or visit

About Ultradent Products, Inc.
Ultradent Products, Inc. is a leading developer of high-tech dental materials, devices and instruments worldwide. Ultradent’s mission is to improve the level of dental health care and to make dental procedures more predictable and hassle free. Consistent with its mission, Ultradent works to improve the quality of life and health of individuals through financial and charitable programs. For more information about Ultradent, call 800.552.5512 or visit

Wednesday, March 14, 2018

Colgate® Announces Recipients of the CARE Grant Program Colgate Award for Research Excellence



Colgate is pleased to announce this year’s recipients of the Colgate Award for Research Excellence (CARE). The CARE Program recognizes a new generation of academic researchers by providing up to $30,000 USD (per project) to support oral health research projects across multiple disciplines.

The five proposals were selected by an esteemed group of senior academic dental researchers from a large pool of submissions. The five researchers to receive Colgate’s CARE program funding this year are:

Dr. Jin-Hee Kwak—University of California at Los Angeles (UCLA), School of Dentistry Research Topic: “ BP-NELL-PEG Therapy to Regenerate Craniofacial Bones.”

Dr. Kuei-Ling (Christine) Hsu—University of Maryland, School of Dentistry
Research Topic: “Transcriptomic and Metabolomic Profiling of the Oral Microbiome in Socially Disadvantage African American Children with Early Childhood Caries.”

Dr. Tamanna Tiwari—University of Colorado, School of Dental Medicine 
Research Topic: “A Participatory Approach in Improving Dental Health in African Immigrants.”

Dr. David Prince—Roseman University, College of Dental Medicine  
Research Topic: “Silver Diamine Fluoride and the Elderly.”

Dr. Cristina Vidal—University of Iowa, College of Dentistry 
Research Topic: “Development of Therapeutic Nanoparticles for Sustained Delivery of Proanthocyanidins in Adhesive Interfaces.”

Proposals were reviewed by a panel of independent reviewers who are non-Colgate researchers. Winners were selected based on program criteria which included innovation, clinical significance, originality and scientific quality. CARE grants are typically offered for periods of 12 months.

“The CARE Program fosters the development of junior faculty by providing seed research funding to emerging leaders in academia at a time in their career path when it is most needed,” said Maria Ryan, Vice President and Chief Dental Officer, Global Technology at Colgate. “Every year, we look forward to meeting and supporting talented researchers in the early stages of their careers by helping to fund innovative projects that promise to advance industry knowledge and perhaps even revolutionize the field of dentistry. On behalf of Colgate, sincere congratulations to the winners of this year’s grant awards.”

Established in 2016, the Colgate CARE Program is designed to foster clinical and scientific research by providing financial support to young academic researchers. In order to be eligible for the Colgate CARE grant, faculty applicants must be in the first five years of an academic appointment.

For more information about the Colgate CARE Program for Young Academic Researchers and application guidelines, click here or visit


Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Elmex, Meridol, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet and Hill’s Ideal Balance. For more information about Colgate’s global business, visit the Company’s web site at To learn more about Colgate Bright Smiles, Bright Futures® oral health education program, please visit

Tuesday, March 13, 2018

Darby Dental Supply Launches New Surgical Division



Darby Dental Supply, one of the nation’s largest dental distributors, announces the launch of a new surgical division. The comprehensive division encompasses over 5,000 top-tier branded products in categories such as instrumentation, sutures, bone grafting, and other surgical-specific areas.

To accommodate the new division, Darby hired a dedicated team of Surgical Account Managers, each of whom have undergone a full year of specialized surgical product training in order to provide expert customer service and knowledge regarding dental surgery and implant procedures.

“In the past, customers in the oral surgery space might have had to call one company for surgical instrumentation, another for bone grafting, a third for sutures, and sometimes others just to fulfill all their surgical needs,” stated Brian Kacerow, Surgical Category Manager, Darby Dental Supply. “Darby’s surgical division eliminates the inconvenience of shopping around by providing a one-stop shop for GPs, Implantologists, and Surgical Specialists.”

The new division is the latest in Darby’s expansion into a full-service solutions provider, further meeting the needs of general practitioners and specialists by adding to the Company’s growing ecosystem of offerings. The Company recently expanded its capital equipment division, formed an exclusive partnership with Dental Fix Rx to provide equipment service, and launched Darby TechForce®, the Company’s new technology services division providing HIPAA compliance, IT managed services, installations, digital integration, and network security solutions.

For more information on Darby’s surgical division as well as its ever-expanding solutions for dental professionals nationwide, please visit

Monday, March 12, 2018

The Dental Industry’s Only News Aggregation And Social Engagement Forum App Launches To Simplify Life and Connect Users

SWYP Dental.png

The concept of “news aggregators” has been around for a while now.  However, many of them are no longer around, and those that remain are a bit clunky and not very specific.  However, a new company has come to market with an aggregator that is specific to the dental industry.  It’s called SWYP and is available now.  The service is device agnostic, meaning you can access their website or use apps for Android or iOS to get to the content.



Designed for busy dental professionals using mobile devices and tablets, SWYP Dental transforms the reading, learning, and social media experience

 – SWYP Dental simply and elegantly combines the beauty of print magazines with the power and convenience of digital and social media. SWYP collects dental content (articles, news, blogs, podcasts) based on user-selected preferences and then delivers the customized content in an App or desktop website. Free to download, SWYP is for all dental professionals including dentists, dental assistants, hygienists, office managers, dental labs, industry professionals, and more. It will revolutionize and transform the way dental professionals consume information.

SWYP contains content from around the dental web on topics you’d expect like Digital Dentistry, Hygiene, Practice Management, and more. It even mixes in topics from outside the industry like finance, business ownership, internet marketing, motivating employees, health & fitness, travel, and more.

“We’re solving the problem of information overload that plagues us all. No one has time for content they aren’t interested in”, states Matthew Petchel, SWYP CEO. “SWYP solves that problem because our users only see content they are interested in based on their preferences and behavior in the app. The future isn’t about spending time looking for content. The future is about having interesting, relevant, and timely content finding you. Think of SWYP as a targeted information funnel for the entire dental industry.”

SWYP also share totally original content from the next wave of influencers to give a more complete, up-to-date view of the dental industry. In addition, SWYP has a community Q&A Forum for users to ask questions and engage with one another to earn points redeemable for rewards. SWYP is also ‘the dental search engine’ that delivers the most relevant results for dental topics. Dental professionals can finally focus all of their attention on the specific information they want to help them be a better dentist, a better hygienist or assistant, and better business leader.

SWYP was founded by industry veterans; Tony Stefanou, Ekram Khan, Jim Arnold, and Matthew Petchel with a combined 97 years in the dental industry. Their experience combines clinical, marketing, industry, and technology expertise.

SWYP is available for both iOS and Android devices and can be downloaded at

SWYPDental everything…all in one app™.


About SWYP
SWYP is a community of dental professionals that lives and breathes within a mobile app and desktop website. SWYP is a Dental News Aggregator and Q&A Community Forum combined and targeted to the dental industry.
SWYP – Dental everything…all in one app™

Thursday, March 8, 2018

KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

KenPharm Logo.jpeg

Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA


CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz™ for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.  Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).  

“The approval of Apadaz is a significant milestone for KemPharm as it creates the opportunity to introduce what we believe is a differentiated product for the short-term management of acute pain,” said Travis Mickle, Ph.D., KemPharm President and Chief Executive Officer.  “Based on its unique properties, we firmly believe there is a commercial pathway for Apadaz in what is a very high-volume market.  We are excited by the opportunity Apadaz offers to patients and for physicians who now have the option of prescribing a differentiated product.”

“In addition to today’s approval, the U.S. Drug Enforcement Administration (DEA) has indicated that it is their intent to schedule Apadaz as a C-II product and will provide an allocation of the Active Pharmaceutical Ingredient (API) consistent with those scheduling provisions,” added Dr. Mickle.  “This prompt decision by the DEA essentially completes the regulatory process with both Agencies and allows us to shift our focus towards the product launch.”

“Finally, today is a validation of KemPharm’s groundbreaking LATTM (Ligand Activated Therapy) platform and our technological approach to drug development,” Dr. Mickle closed.  “KemPharm is first and foremost a prodrug development company.  The Apadaz approval highlights the value potential that LAT™ offers in the discovery and development of proprietary prodrugs that are designed to be differentiated versions of widely prescribed, currently approved drugs, and that can successfully complete the rigorous regulatory process.”


Apadaz was developed from KemPharm’s proprietary LATTM (Ligand Activated Therapy) platform technology and is intended for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. KemPharm believes Apadaz is unique among prescription opioids in that it contains a prodrug that is chemically inert, or inactive, on its own.  When ingested, enzymes in the gastrointestinal tract cleave the ligand from the prodrug (benzhydrocodone) and release the parent drug (hydrocodone), which can then exert its therapeutic effect.  The final approved product labeling for Apadaz includes these and other data points but concludes that the overall results of the clinical program did not demonstrate abuse-deterrence by current measurement standards.

The approval of Apadaz via the 505(b)(2) pathway was based in part on pharmacokinetic studies with Vicoprofen®, Ultracet®, and Norco® in which Apadaz demonstrated exposure to hydrocodone and acetaminophen (APAP) that is expected to result in therapeutic effects equivalent to currently approved immediate-release hydrocodone/APAP combination products when administered orally as intended.

Apadaz contains an opioid agonist and acetaminophen and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Apadaz for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not been or are not expected tolerated, or have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Important Safety Information:

Apadaz is contraindicated in patients with: significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity to hydrocodone or acetaminophen.

Apadaz contains benzhydrocodone, a Schedule II controlled substance.  Apadaz can be abused and is subject to misuse, addiction, and criminal diversion.

Potential risks associated with Apadaz include addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, risks of concomitant use or discontinuation of cytochrome P450 CYP3A4 inhibitors and inducers, acetaminophen hepatoxicity risks from concomitant use with benzodiazepines or other CNS depressants, risk of life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients, adrenal insufficiency, severe hypotension, serious skin reactions, risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness, hypersensitivity/anaphylaxis, risks of use in patients with gastrointestinal conditions, risk of use in patients with seizure disorders, and withdrawal, risks of driving and operating machinery. 

Potential drug interactions with Apadaz include:

Serotonergic Drugs: Concomitant use may result in serotonin syndrome.  Discontinue Apadaz if serotonin syndrome is suspected.
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Apadaz because they may reduce analgesic effect of APADAZ or precipitate withdrawal symptoms.
Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.
Most common adverse reactions (>5%) are nausea, somnolence, vomiting, constipation, pruritus, dizziness, and headache.

The Full Prescribing Information for Apadaz contains the following Boxed Warning:


Addiction, Abuse, and Misuse:

Apadaz exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Apadaz and monitor all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression:

Serious, life-threatening, or fatal respiratory depression may occur with use of Apadaz.  Monitor for respiratory depression, especially during initiation of Apadaz or following a dose increase.

Accidental Ingestion:

Accidental ingestion of even one dose of Apadaz, especially by children, can result in a fatal overdose of hydrocodone.

Neonatal Opioid Withdrawal Syndrome:

Prolonged use of Apadaz during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.  If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Cytochrome P450 3A4 Interaction:

The concomitant use of Apadaz with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving Apadaz and any CYP3A4 inhibitor or inducer.


Apadaz contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants:

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Reserve concomitant prescribing of Apadaz and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Limit dosages and durations to the minimum required.
Follow patients for signs and symptoms of respiratory depression and sedation.
For Important Safety Information including full prescribing information, visit:

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology.  KemPharm utilizes its proprietary LATTM platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD.  In addition, the company has received FDA approval for Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both Apadaz™ and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2016, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission.  KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Wednesday, March 7, 2018

Ultradent Introduces Peak®-ZM Zirconia and Metal Primer

Peak ZM_Syringe and Bottle_0717.jpg

Ultradent Products, Inc., is pleased to introduce Peak®-ZM zirconia and metal primer. Peak-ZM primer is specifically designed to provide high adhesion between zirconia and metal surfaces and the luting material. Thanks to the chemistry containing the MDP monomer, Peak-ZM primer can increase bond strengths five times compared to using a resin cement alone.1 With Peak-ZM primer, clinicians can feel confident in their zirconia and metal restorations.

Peak-ZM zirconia and metal primer is a single component surface treatment that enhances bond values when applied to zirconia, alumina, and metal/alloys. It contains a blend of monomers, including 10-methacryloyldecyl dihydrogen phosphate (MDP), which produces a chemical bond that significantly increases adhesion between resin-based material and the bonding surface of the restoration. It also features a smart chemistry that includes in-house, custom-synthesized monomers that help enhance its bond strength.

Peak-ZM primer is available in convenient 4 ml bottles (300 uses) and 1.2 ml syringes (100 uses).

To learn more about Peak-ZM primer, call 800.552.5512, or visit

Tuesday, March 6, 2018

Opalescence® PF Tooth Whitening System Unveils New Packaging

Opalescence PF New Packaging.jpg

Ultradent Products, Inc., is pleased to unveil new packaging for its hallmark professional take-home tooth whitening system, Opalescence® PF whitening. Opalescence PF whitening system’s new look showcases a modern, sophisticated, clean esthetic and utilizes less plastic than its predecessor. The new packaging also features a nesting concept, which maximizes space and gives each product element a designated place for easy access and product storage. The box uses an invisible magnetic closure, making it easy and desirable to save and reuse, adding to the environmentally friendly, contemporary appeal.

The Opalescence PF tooth whitening system has ranked as the number one professional whitening system worldwide since its release in 1990. The award-winning system features customized take-home whitening trays with syringe-delivered whitening gel. Opalescence whitening gel is known for its sticky, viscous texture which allows it to stay put on the tooth instead of migrating to tissues to provide maximum whitening results with minimum sensitivity. Newest to the Opalescence PF whitening brand is Opalescence® Quick—a 45% carbamide peroxide whitening gel with a 15–30-minute wear time that is now part of Opalescence PF’s take-home line of products. It comes in a Mint flavor. PF whitening also comes in 10%, 15%, 20%, and 35% carbamide peroxide concentrations, in both Regular, Mint, and Melon flavors. The product also contains potassium nitrate and fluoride.

Opalescence PF tooth whitening system is recommended for whitening discolored teeth prior to placement of composite, veneers, or crowns. It is effective in removing some or all internal tooth discolorations due to congenital, systemic, pharmacologic, and traumatic factors, as well as aging. It has even been successful in resolving staining due to fluorosis and tetracycline.1,2

To learn more about Opalescence PF tooth whitening system and to check out its new packaging, visit the Ultradent Booth #3811 at the 2018 Chicago Midwinter Show, call 800.552.5512, or visit
About Ultradent Products, Inc.
Ultradent Products, Inc., is a leading developer and manufacturer of high-tech dental materials, devices, and instruments worldwide. Ultradent’s vision is to improve oral health globally. Ultradent also works to improve the quality of life and health of individuals through financial and charitable programs. For more information about Ultradent, call 800.552.5512 or visit

Monday, March 5, 2018

Darby Dental Supply Continues West Coast Expansion with Acquisition of SmartPractice® Dental Supply Division

Darby Logo.jpeg


Darby Dental Supply, one of the nation’s largest dental distributors, announces its planned acquisition of the dental supply division of Phoenix-based SmartPractice.
This acquisition and the resulting strategic partnership capitalize on each company’s core competencies with Darby leveraging SmartPractice’s acclaimed glove expertise and manufacturing capabilities. SmartPractice’s supply and glove customer base will benefit from Darby’s expansive state-of-the-art distribution network, extended product lines, capital equipment, technology services, and equipment service.
The agreement with SmartPractice is Darby’s latest endeavor to partner with companies who have select areas of industry expertise. Darby customers will gain direct access to SmartPractice’s premier line of specialized gloves.

With this acquisition, Darby will be expanding its Chandler, Arizona facility to provide customers with additional services while extending its hours of operation. Additional sales, customer care, and support services will join the Arizona team to provide convenient access for customers across the country. The transaction fuels Darby’s growth strategy to extend its ecosystem of full service solutions, while supporting its ongoing West Coast expansion.

“This investment further strengthens Darby Dental Supply’s position as an industry leader and ensures that our customers have access to continually-expanding products, advanced services, and the expertise upon which they have relied for 70 years,” stated Michael Ashkin, Chairman, Darby Group Companies, Inc. “For three generations, and looking to the fourth, the Ashkin family has been focused on providing our customers with outstanding value, an exceptional customer experience, and innovative technological solutions. This would not be possible without the hard work of our talented employees. We are excited to welcome the SmartPractice dental supply team into our extended family.”

“With our rich history of accomplishments for nearly 50 years, SmartPractice has only just begun to realize our full potential of improving healthcare practices to improve world health. Through this strategic relationship, Darby Dental will be partnering with us as an additional provider of SmartPractice gloves to the dental industry. Our legacy of pioneering award-winning gloves that meet the unique needs of the dental community will now have a broader reach,” remarked Dr. Curt Hamann, President, CEO, and Medical Director of SmartPractice. "Additionally, our team continues to capitalize on our existing resources to develop an array of products and services that improve active patient counts, simplify brand management and ensure an easy ordering experience."

Darby has consistently advanced its business model to meet customer demand for timely, best-in-class solutions. The company recently expanded its specialty product offerings, added a capital equipment division, formed an exclusive partnership with DentalFix RX to provide equipment service, and in January 2018 debuted Darby TechForce®, the company’s new technology services division providing HIPAA compliance, IT managed services, installations, digital integration, and network security solutions. As customers seek out more convenient ordering channels and faster response times, Darby’s investment in technological solutions allows them to personalize the way they do business. The Company recently launched a new user-optimized website, mobile website, and a mobile app, complete with an inventory management system.
The transaction is expected to close in May of 2018.

About Darby Dental Supply, LLC
Darby Dental Supply, LLC, is one of the largest dental distributors in the United States, shipping over one million orders each year. Headquartered in Jericho, NY, the company was founded in 1948 and has seven sales offices and three fully-automated distribution centers strategically positioned across the country. With over 45,000 products in stock, Darby services the general practitioner as well as numerous specialties. In addition to Darby’s supply vertical, the company also hosts a technology services division (Darby TechForce®), a capital equipment division, equipment repair services (through an exclusive partnership with DentalFix RX), and a full line of private label products. For more information about Darby, please visit

About SmartPractice
SmartPractice® is a family-owned company serving dental, veterinary, dermatology, allergy and healthcare professionals globally with patient communications, practice marketing, exam gloves and medical supplies that include T.R.U.E TEST and other skin patch testing supplies. Since 1969, the Phoenix, AZ-based company has been driven by its mission for healthier practices and healthier patients. The company has received consecutive national awards for its innovative glove solutions, print manufacturing excellence, corporate philanthropy and employee wellness programs. For more information about SmartPractice, visit

Thursday, March 1, 2018

Introducing DEXIS FS Ergo by KaVo – A New Class of Digital Sensors

Kavo FS Ergo.jpg
Have you ever wanted a more comfortable digital x-ray sensor?  I think that’s a question that lots of dentists and staff ask themselves.  Now DEXIS has introduced the DEXIS FS Ergo, which looks to be the next big thing in digital radiography.  Read on for all the details!

KaVo Kerr, an organization comprised of two global leaders in dentistry, is pleased to unveil the expansion of its growing portfolio of imaging solutions at this year’s Chicago Midwinter dental meeting with the new DEXIS FS Ergo by KaVo. Built upon the award-winning DEXIS PerfectSize™sensor and TrueComfort™ design, the FS Ergo stands as the latest innovation to redefine patient comfort and create a new class of digital sensors. FS Ergo combines innovative design and skillfully engineered components to add ease and flexibility to thepatient experience. The sensor provides significant improvements in comfort for patients with low tolerance for standard intraoral modalities, allowing for a more pleasant sensor placement that patients will remember.

A robust, durable device that maintains optimal image integrity, FS Ergo features:

  • Sensor Housing – resistant to bite marks, the submersible sensor housing can also withstand a wide variety of disinfection chemicals.
  • Cable-To-Sensor Connection – equipped with connectivity proven successful under rigorous testing to such forces as pulling, twisting, straining, and bending.
  • USB Connector – built to withstand high frequency insertion and pulling cycles, the USB connection adds to the overall durability of the sensor.
  • Contoured Positioning System – made from advanced materials, the positioning system allows the sensor to easily exit and protects the longevity of the cable from wear and tear.

DEXIS FS Ergo by KaVo helps to reduce retakes due to patient movement caused by discomfort thereby enhancing practice efficiency and creating a streamlined digital workflow. By pairing the newly developed flexible sensor technology with a soft housing, FS Ergo can “give” as X-rays are being captured. Even the proprietary holder system is uniquely designed to accommodate the flex of the sensor so that it can adapt to your patient, and thus offer the best radiographic experience possible. “DEXIS products have always instilled confidence in patients and practitioners, and FS Ergo by KaVo will reinforce their beliefs,” stated Insiyah Ahmedi, Sr. Marketing Manager, KaVo Kerr Intraoral Imaging. “The complete line of DEXIS imaging products has continually displayed the ability to innovate and excite with digital solutions that consistently provide highly diagnostic information crucial for patient care." Dental professionals are encouraged to experience how the FS Ergo can work for them.


To learn more about the DEXIS FS Ergo by KaVo, please visit

Wednesday, February 28, 2018

NuSmile Launches I Love My NuSmile Program


HOUSTON, TEXAS, February 21, 2018—NuSmile Ltd., the worldwide leader in pediatric esthetic restorative dentistry, announced today the launch of its I Love My NuSmile program. The centerpiece of the program is the new I Love My NuSmile website that not only helps parents understand the best restorative dental options available for their children, but also provides a locator feature that makes it easy to find expert providers with nearby dental practices that offer NuSmile’s market-leading esthetic pediatric crowns. Dentists will be able to register for the locator beginning March 1, 2018. Once registered, they will work with a NuSmile team member to personalize their contact information, upload a photo and write their own practice description. The website is expected to be announced to the public in April 2018 through several forms of digital and print media.

“Unfortunately, parents of children affected by early childhood caries are often unaware of esthetic treatment options for their child,” said Diane Johnson Krueger, NuSmile founder and CEO. “That’s why we’ve decided to make it easier than ever for parents to learn more about esthetic restorative solutions, and to locate children’s dentists nearby who offer them.” She added, “Children whose decayed teeth are plainly visible are often subjected to teasing and even bullying, which can inflict severe emotional pain to both the child and the parents. Having to wear ‘silver’ crowns or fillings can be equally traumatic. Also, inferior quality esthetic crowns that are less durable than NuSmile ZR or Signature crowns increase the likelihood of retreatment, which no parent wants. No child or parent should have to go through that kind of embarrassment or emotional stress.”

According to Mike Loessberg, NuSmile Director of Sales, North America, the experience available to parents who visit will be unlike that provided on any other pediatric crown website. “This special website has been created expressly to help parents quickly grasp the pros and cons with photographs showing treatment outcomes of various restorative options for their child.” He added, “They’ll also learn why NuSmile’s ZR zirconia crowns and Signature pre-veneered crowns are the world’s most popular esthetic pediatric crowns, and why these crowns are consistently shown in clinical evaluations and dentist polls to be number one in durability, esthetics and fit.”

As Mr. Loessberg pointed out, “This consumer-focused approach has been incredibly successful in the orthodontic clear aligner market, and we see no reason why it won’t also be a huge success with parents who are looking to find the best restorative treatment options for their child.”

Ms. Krueger predicted that dentists will love I Love My NuSmile as much as parents will. “We’re going to make a significant investment in advertising that draws parents to the I Love My NuSmile website, where our dentist locator will point them toward nearby dental practices that offer our state- of-the-art crowns and related products. This program is a powerful tool to help some of the best
children’s dentists connect with even more of the patients who really need them. We couldn’t think of a better way to honor our customers and the incredible work they are doing,” she said.

For more information about this new program, please visit For more information about NuSmile, please visit

About NuSmile

Founded in 1991 in Houston, Texas by Diane Johnson Krueger, NuSmile is the worldwide leader in pediatric esthetic restorative dentistry. Shortly after its founding, the company invented its first esthetic pediatric crown; more than 4 million have been used in restorations in the 25 years since. The company’s current offerings include the NuSmile ZR Zirconia crown system, featuring Try-In crowns to prevent saliva/blood contamination and NuSmile BioCem® BioActive Cement for exceptional bond strength and handling; NuSmile Signature Pre- veneered crowns; NuSmile SSC Pre-contoured crowns; and NuSmile NeoMTA® pulp therapy medicament. NuSmile prides itself on its passion for customer care, its unwavering commitment to research and education, and its unmatched support for the American Academy of Pediatric Dentistry (AAPD), the International Association of Pediatric Dentistry (IAPD), the Canadian Academy of Pediatric Dentistry/Académie Canadienne de Dentisterie Pédiatrique (CAPD/ACPD) and several other organizations dedicated to the dental care of children and the dentists who serve them.

Tuesday, February 27, 2018

The other side of the opioid epidemic — we're people in severe pain

Over the last few years, we’ve all been inundated with horror stories and sad tales dealing with the “opioid epidemic”.  However, one thing that has been tragically overlooked in all of this is the fact that there are fellow human beings out there with legitimate needs for pain management.  Like any type of socio-political subject, this one has many twists and turns.  As you attempt to cutoff the supply to the abusers, you also cut the supply to those in legitimate need.  Or, even worse, those with legitimate needs are classified as abusers.  I find it a bit ironic that as the prescribing of opiates and opioids has decreased, the import and distribution of heroin has increased and the price of heroin has dropped.  The sad fact is that as legitimate pain suffers are cut off from their meds, some, in dire desperation, will turn to heroin.  That’s because, despite its horrors, heroin is a decent pain reliever.
Or… let’s take this argument to an absurd extreme.  Suppose that somehow, someway, insulin is suddenly a chemical that could be used to create a horrible substance like meth.  Would anyone support eliminating the prescribing of insulin because there might be some bad stuff that could be done with it?  
Now, let me make myself clear.  I completely and totally support responsible prescribing.  What happened in the early 2000s with pill mills was a disgrace to anyone who is a doctor.  However, we definitely want to make sure that, in our rush to fight an “epidemic” we do not damage those who were the original benefiters of those very same drugs.
With all of that in mind, please read the following editorial that appeared on The Hill.  The author, Kate Nicholson, is a civil rights attorney, a nationally-recognized expert in the Americans with Disabilities Act, and a chronic pain survivor.  She has written an incredible article here about the part of pain meds that very few are talking about nowadays…

When I went into the office one Saturday afternoon in August 1994, I planned to spend a few hours finishing a brief that was due in federal court Monday morning.

At the time, I was an attorney for the justice department.  After 30 minutes of working at my desk, my back started to burn; it felt as if acid were eating my spine. In rapid succession, my muscles seized and threw me from my chair. I landed on the floor, stunned, as my body seared with pain.

What I didn’t know then was that the pain would persist, and that I would be unable to sit, stand, or walk unassisted for almost twenty years. Nor could I have imagined that I would take opioids.

Opioids fill the news with a steady stream of stories of lives lost from overdose and abuse. What we rarely hear is the other side — opioids are also the most powerful pain medication we have. For me, they were life-restoring.

Appropriate pain management that included prescription opioids lifted me from the desperate circumstances of being bedridden and unable to sleep for months at a time to someone who negotiated major settlement agreements. I argued important cases in federal court, and supervised thousands of matters in U.S. Attorney’s Offices across the country. 

I still could not sit or stand — I negotiated via video-teleconference, argued from a reclining lawn chair, and managed cases from a jerry-rigged, platform bed — but I could and did work and function.

Pain patients today are not so fortunate.  In our effort to thwart the genuine problem of drug overdoses, we are taking life-sustaining medicine away from suffering people.

Long-term, legitimate pain patients who have relied on opioid analgesics can no longer fill their prescriptions in the many states that set maximum dosage and supply limits, often of three to seven days.

Even in states that contain exceptions for long-term pain care, insurance companies and pharmacy policies use such laws as a reason to deny coverage or fills. Pain patients are being denied treatment and involuntarily tapered off of opioid medications, even if they’ve never shown any risks of abuse.

The Department of Veterans Affairs, which sponsored one of the first systematic efforts to discontinue opioid treatment, recently issued an abstract reporting that the results were not fewer overdose deaths but increased suicide mortality.

While there is no question that looser prescribing of opioids in the 1990s and early 2000s contributed to the overdose crisis, illegal fentanyl and heroin drive overdoses today, not new prescriptions.  

The prescribing of opioids has dropped every year since 2012 and is at 10 year low — and yet drug overdose deaths have skyrocketed. Meanwhile, our public policy looks backward in time, intruding on the doctor patient relationship and burdening patient care.

The Attorney General recently responded to the concerns of pain patients by telling them to “take a few Bufferin or something and go to bed.”  

His comment shows an astonishing misunderstanding of a condition whose quality of life index (QLI) is akin to that of late-stage cancer. Fifty million Americans suffer from severe or persistent pain, which twenty-five times more than those who misuse opioids.

Chronic pain is also the primary cause of disability in the US, and it costs the economy half a trillion dollars every year.

There is an important but often glossed over distinction between using medication for a health condition in a way that restores function, enabling work and participation in family life, and misusing a substance in a manner that destroys function.

Most people who take opioids for pain do not abuse them: studies show risk for addiction in such patients varying between .07 and 8 percent. And, when opioids are prescribed properly with screening and follow through care, the risk of addiction goes down significantly.

The substantial majority of people who have misused prescription opioids never received them in a healthcare setting; they obtained them from medicine cabinets, family and friends, or bought on the street.

Like many pain patients, I initially resisted taking opioids. I exhausted every other possible treatment first.

Because my condition resulted from a surgery when a doctor severed nerve plexuses in my spine, I tried infusions, nerve blocks and even a repeat surgery. I did physical therapy, acupuncture, and biofeedback. But nothing abated the pain.  

Treatment with opioids and integrative care allowed me to maintain a job, a sense of purpose, and community until I found my way to healing.  Mine is a story rarely told of someone who took opioid analgesics for years and went off them without incident when the pain remitted.  Given the environment today, such stories may well become extinct.

Kate Nicholson is a civil rights attorney, a nationally-recognized expert in the Americans with Disabilities Act, and a chronic pain survivor. She is writing a book about pain, and recently gave a TEDx talk on the subject.

Monday, February 26, 2018

Darby Dental Supply Expands Capital Equipment Offerings with Complete Air Techniques Line


Darby Dental Supply, one of the nation’s largest distributors of dental supplies and services, recently expanded its equipment portfolio to include the full line of Air Techniques products. This addition is the latest advancement in Darby’s aim to partner with leading manufacturers and suppliers to strengthen its position as a single-source solution for supplies, services, and capital equipment.

Darby launched its capital equipment division in 2009 and has been continuously focused on expanding its product lines and services to become a leading resource in capital equipment. 
In 2016, Darby announced an exclusive partnership with equipment repair leader Dental Fix Rx, allowing Darby to expand its customer offerings to include nationwide equipment service, installation, and repair. The partnership will now allow Darby customers to receive expert installation on all Air Techniques equipment.

“Darby is constantly striving to provide our customers with everything they need for their practice,” remarked Scott Walsh, VP of Sales, Darby Dental Supply. “This latest expansion with Air Techniques solidifies Darby as a key player in the capital equipment arena.”

Partnering with industry-leading manufacturers like Air Techniques strengthens Darby’s ability to meet increased customer demand for fully integrated solutions. In addition to its recent capital equipment expansion, the Company also invested in a new user-optimized website and mobile app, expanded its specialty product offerings, and debuted Darby TechForce®, the Company’s new technology services division.

About Darby Dental Supply, LLC

Darby Dental Supply, LLC, is one of the largest dental distributors in the United States, shipping
over one million orders each year. Headquartered in Jericho, NY, the Company was founded in
1948 and has seven sales offices and three fully automated distribution centers strategically
positioned across the country. With over 45,000 products in stock, Darby services the general
practitioner as well as numerous specialties. In addition to Darby’s supply vertical, the Company
also hosts a technology services division (Darby TechForce®), a capital equipment division,
equipment repair services (through an exclusive partnership with Dental Fix Rx), and a full line
of private label products. For more information about Darby, please visit

About Air Techniques, Inc.

For over 55 years, Air Techniques, Inc. has exceeded their customers’ expectations by delivering innovative, high quality products that advance the standard of dental care. With breakthrough solutions in Digital Imaging – delivering uncompromising image quality for precise patient diagnosis; Utility Equipment – best-in-class infrastructure that keeps dental practices operating at peak performance; and Infection Prevention Products – providing exceptional patient care while protecting the clinical staff, Air Techniques ensures today’s dental professionals are “Equipped for Life”® earning trust through ingenuity, innovation, and stellar service. For further information about Air Techniques, please visit

Friday, February 23, 2018

Introducing Amabrush: the World’s First Fully Automatic Hands-Free Toothbrush


Simultaneously and Thoroughly Cleans all Teeth in Just Ten Seconds!

 Amabrush, the world’s first fully automatic toothbrush, was officially launched in the US market at this year’s Chicago Midwinter dental meeting. Amabrush is a revolutionary hands-free toothbrush that simultaneously brushes all teeth in a mere ten seconds. Simply press a single button and the innovative Amabrush technology works to effectively and efficiently clean all teeth and gums, practically eliminating the extra time, and human error often experienced with traditional brushing methods.
Amabrush was first conceptualized in 2015 by a team of engineers and healthcare professional visionaries whose goal was to simplify the tooth brushing routine. The creators brought Amabrush to Kickstarter in July of 2017 and were fully funded within one hour.
“We all know that we need to brush our teeth. Whether we’re skipping brushing, not brushing long enough, or not brushing correctly, many of us simply don’t get our teeth as clean as they should be. Amabrush aims to change all that,” remarked Amabrush Founder and CEO, Marvin Musialek. “At first people are always a bit skeptical about whether Amabrush is too good to be true but proof of efficacy is clearly revealed in the ongoing positive results of our constant clinical testing, as well as consistent feedback received from completely amazed and 
satisfied users.”
Multiple rows of soft antibacterial Amabrush bristles are directed in a 45° angle against the 
gumline, simulating the widely recommended Bass method of brushing. With an amplitude of 9.5G, Amabrush creates a variety of vibrations that oscillate with different resonant frequencies to gently yet effectively clean each quadrant of the mouth. Subtle vibrations oscillate the bristles, effectively removing plaque and bacteria on the teeth as well as along the gumline. Unlike nylon bristles, soft Amabrush bristles gently rub as opposed to scratch surfaces, further eliminating any risk of damage to the teeth and gums.
Amabrush is comprised of three components:
• Anti-Bacterial Mouthpiece – The one-size-fits-all mouthpiece is made of a flexible antibacterial silicone material that wards off 99% of bacterial agents found in between bristles. Strategically arranged soft 3D bristles are gentle enough to prevent enamel and gum damage yet strong enough to thoroughly clean both teeth and gums. Built-in micro-channels are made to transport an ideal amount of specially formulated Amabrush toothpaste. The Amabrush mouthpiece is cleaned using traditional rinsing methods as you would with regular toothbrushes.
• Handpiece – The Amabrush handpiece magnetically connects to the mouthpiece. The handpiece acts as the dispenser for Amabrush toothpaste capsules, and also houses the exclusive Amabrush tooth brushing technology. The handpiece comes with a built-in low-energy wireless charging module (Qi standard), and is equipped with Bluetooth® as well as an Amabrush App. A fully charged battery lasts for approximately one month.
• Toothpaste Capsules – Amabrush toothpaste capsules are simply placed into the handpiece and a built-in mechanism foams and automatically delivers the ideal amount of toothpaste to the mouthpiece each and every time. The FDA-approved toothpaste is specially formulated for the system. Amabrush toothpaste is available in whitening, sensitive, and extra fresh. A single toothpaste capsule lasts for up to a month.
Amabrush is simple to use:
Step 1 – Attach the handpiece to the mouthpiece
Step 2 – Insert the mouthpiece into the mouth and bite down
Step 3 – Push the button on the handpiece to dispense the toothpaste foam
Step 4 – Wait ten seconds
Step 5 – Spit and rinse
“Although ten seconds may not sound like much, keep in mind that each tooth is actually being cleaned for that duration,” remarked Dr. Hady Haririan, Amabrush Advisor and dentist. “Brushing with a traditional toothbrush may last longer but you aren’t brushing all of your teeth at once. Adults have 32 teeth and each tooth has three surfaces. If you brush for 120 seconds, each surface gets brushed for just 1.25 seconds. Amabrush cleans all of your teeth’s surfaces for ten whole seconds. This means that every tooth surface gets brushed eight times longer, while the total tooth brushing duration is twelve times faster.”
All Amabrush units come equipped with a sound and light indicator to provide various alerts and information including current battery status, finished tooth brushing sessions, and operational errors. Users can further personalize Amabrush by setting various vibration modes (such as gum massage and burst mode), configure cleaning time, and much more!
All Amabrush units can be equipped with a carry case for on-the-go use. What's more, an Amabrush tongue cleaner is also available to keep the tongue smooth and clean, as well as a UV sanitation station that sterilizes up to two mouthpieces with ultraviolet light (185nm).
Amabrush is currently available at, and the Company is presently working to further expand its availability to dental professionals and consumers through additional convenient sales channels.
For more information about Amabrush, please visit
About the Amabrush Team
The Amabrush team has a strong background in healthcare, product design, and mechanical engineering. Founder Marvin Musialek developed the first Amabrush prototype in 2015. Together with Martin Forstenpointner, a mechanical engineer, and Alexander Stummer, a biomedical engineer, Amabrush was gradually brought to fruition. Advised by Dr. Hady Haririan, a periodontist and member of the Medical University of Dentistry in Vienna and Austrian Society of Periodontology, the team tirelessly tested Amabrush to bring it to the successful oral health aid that it is today. The Amabrush team continues to work closely with medical universities, dentists, and beta testers to consistently evolve its effectiveness and efficiency as a superior oral health aid for optimum oral health. Amabrush is fully supported and funded by the Austrian government, private institutions, and the European Commission. For more information about Amabrush, please visit

Thursday, February 22, 2018

Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018

Here is some interesting info courtesy of the Centers for Disease Control and Prevention.  It seems that with this year’s intense and difficult flu season, the success of the flu vaccine has been a bit limited.  The vaccine overall is “only 36 percent effective”.  However, there’s a lot more data on the vaccine than just that.  Read on for info from the CDC:

In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). During each influenza season since 2004–05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This report uses data from 4,562 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017–February 3, 2018. During this period, overall adjusted vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 36% (95% confidence interval [CI] = 27%–44%). Most (69%) influenza infections were caused by A(H3N2) viruses. VE was estimated to be 25% (CI = 13% to 36%) against illness caused by influenza A(H3N2) virus, 67% (CI = 54%–76%) against A(H1N1)pdm09 viruses, and 42% (CI = 25%–56%) against influenza B viruses. These early VE estimates underscore the need for ongoing influenza prevention and treatment measures. CDC continues to recommend influenza vaccination because the vaccine can still prevent some infections with currently circulating influenza viruses, which are expected to continue circulating for several weeks. Even with current vaccine effectiveness estimates, vaccination will still prevent influenza illness, including thousands of hospitalizations and deaths. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated.

Methods used by the U.S. Flu VE Network have been published previously (2). At five study sites,* patients aged ≥6 months seeking outpatient medical care for an ARI with cough within 7 days of illness onset were enrolled. Study enrollment began after local surveillance identified increasing weekly influenza activity or one or more laboratory-confirmed cases of influenza per week for 2 consecutive weeks. Patients were eligible for enrollment if they 1) were aged ≥6 months on September 1, 2017, and thus were eligible for vaccination; 2) reported an ARI with cough with onset ≤7 days earlier; and 3) had not been treated with influenza antiviral medication (e.g., oseltamivir) during this illness. After obtaining informed consent from patients or from parents or guardians for their children, participants or their proxies were interviewed to collect demographic data, information on general and current health status and symptoms, and 2017–18 influenza vaccination status. Nasal and oropharyngeal swabs (or nasal swabs alone for children aged <2 years) were collected to obtain respiratory specimens; nasal and oropharyngeal swabs were placed together in a single cryovial with viral transport medium. Specimens were tested at U.S. Flu VE Network laboratories using CDC’s real-time reverse transcription polymerase–chain reaction (rRT-PCR) protocol for detection and identification of influenza viruses. Participants (including children aged <9 years, who require 2 vaccine doses during their first vaccination season) were considered vaccinated if they received ≥1 dose of any seasonal influenza vaccine ≥14 days before illness onset, according to medical records and registries (at the Wisconsin site); medical records and self-report (at the Washington site); or self-report only (at the Michigan, Pennsylvania, and Texas sites). VE against all influenza virus types combined and against viruses by type/subtype was estimated as 100% x (1 – odds ratio).† Estimates were adjusted for study site, age group, sex, race/ethnicity, self-rated general health, number of days from illness onset to enrollment, and week of illness (3-week intervals) using logistic regression. Interim VE estimates for the 2017–18 season were based on patients enrolled through February 3, 2018.

Among the 4,562 children and adults with ARI enrolled at the five study sites from November 2, 2017, through February 3, 2018, a total of 1,712 (38%) tested positive for influenza virus by rRT-PCR, including 1,392 (81%) influenza A viruses and 323 (19%) influenza B viruses (Table 1). Among 1,340 subtyped influenza A viruses, 1,143 (85%) were A(H3N2) viruses and 208 (16%) were A(H1N1)pdm09 viruses. Most (98%) influenza B viruses belonged to the B/Yamagata lineage. The proportion of patients with influenza differed by study site, sex, age group, race/ethnicity, self-rated health status, and interval from illness onset to enrollment (Table 1). The percentage of patients who were vaccinated ranged from 45% to 59% among study sites and differed by sex, age group, race/ethnicity, and self-rated health status.

Among ARI patient participants, 43% of those with influenza had received the 2017–18 seasonal influenza vaccine, compared with 53% of influenza-negative participants (Table 2). After adjusting for study site, age group, sex, race/ethnicity, self-rated general health, number of days from illness onset to enrollment, and week of illness onset (3-week intervals), VE against medically attended ARI caused by all influenza virus types combined was 36% (CI = 27%–44%). VE for all ages was 25% (CI = 13% to 36%) against medically attended ARI caused by A(H3N2) virus infection, 67% (CI = 54%–76%) against influenza A(H1N1)pdm09 virus infection, and 42% (CI = 25%–56%) against influenza B virus infection. VE point estimates against medically attended influenza for all virus types varied by age group; statistically significant protection against medically attended influenza was found among children aged 6 months through 8 years (VE = 59%; CI = 44%–69%) and adults aged 18–49 years (VE = 33%; CI = 16%–47%), whereas no statistically significant protection was observed in other age groups.

As of February 3, 2018, a total of 257 influenza A(H3N2) viruses from U.S. Flu VE Network participants had been characterized by CDC; 240 (93%) belonged to either genetic group 3C.2a (226 viruses) or the related subgroup 3C.2a1 (14), whereas 17 (7%) belonged to group 3C.3a. Genetic group 3C.2a includes the A/Hong Kong/4801/2014 reference virus representing the A(H3N2) component of the 2017–18 Northern Hemisphere influenza vaccines (3).
Early and widespread influenza activity during the 2017–18 influenza season provided the opportunity to estimate interim VE against several circulating influenza viruses, including the predominant A(H3N2) virus. These interim estimates reflect ongoing challenges with the A(H3N2) vaccine component since the 2011–12 season. The interim estimate of 25% VE against A(H3N2) viruses this season indicates that vaccination provided some protection, in contrast to recently reported, nonsignificant interim estimates of 17% from Canada and 10% from Australia (4,5) and is similar to final (32%) VE estimates in the United States against A(H3N2) viruses during 2016–17§ (6). However, among children aged 6 months through 8 years, the interim estimates against any influenza and A(H3N2) virus infection were higher; the risk for A(H3N2) associated medically-attended influenza illness was reduced by more than half (59%) among vaccinated children. Also, with interim VE estimates of 67% and 42% against influenza A(H1N1)pdm09 and B viruses, respectively, vaccination provided substantial protection against circulating A(H1N1)pdm09 viruses, as well as moderate protection against influenza B viruses predominantly belonging to the B/Yamagata lineage, the second influenza type B component included in quadrivalent vaccines. CDC continues to recommend influenza vaccination while influenza viruses are circulating in the community; several more weeks of influenza activity are likely. Influenza vaccination has prevented thousands of hospitalizations during previous seasons when influenza A(H3N2) viruses were predominant, including during the 2014–15 season when interim VE estimates were similar to those reported here. Appropriate use of influenza antiviral medications for treatment of severely ill persons or persons at high risk for complications from influenza who develop influenza symptoms is important, especially among older adults, who currently have the highest hospitalization rates (3).

VE estimates against A(H3N2) viruses have been lower than estimates against A(H1N1)pdm09 and B viruses for several years (7). Although there is no definitive evidence for antigenic drift of viruses circulating this season compared with cell culture–propagated reference viruses representing the A(H3N2) vaccine component (3), challenges with antigenic characterization of recent A(H3N2) viruses, many of which could not be characterized using traditional hemagglutination inhibition assays, have required the use of additional virus neutralization assays to assess antigenic characteristics. Multiple factors might be contributing to the reported VE against A(H3N2) viruses this season. Immune responses to vaccination differ by age and previous infection or vaccination history and can affect vaccine protection; higher VE against A(H3N2) viruses among young children suggests that vaccination might provide better protection against circulating A(H3N2) viruses to this age group. Also, genetic changes in the vaccine virus hemagglutinin protein that arise during passage in eggs might result in a vaccine immune response that is less effective against circulating viruses (8,9). Human serologic data indicate decreased inhibition of circulating cell culture–propagated A(H3N2) viruses compared with egg-propagated viruses among persons vaccinated with egg-based vaccines.¶ Additional studies are needed to assess whether VE against circulating A(H3N2) viruses varies by vaccine type, including comparisons between egg-based and non–egg-based vaccines. CDC will continue to monitor VE through the remainder of the season and is investigating these factors. In addition, many efforts are under way to improve selection and development of candidate vaccine viruses that are optimal for vaccine production and provide protection against a majority of circulating viruses.

These interim VE estimates underscore the need for influenza antiviral treatment for any patient with suspected or confirmed influenza who is hospitalized, has severe or progressive illness, or is at high risk for complications from influenza, regardless of vaccination status or results of rapid, point-of-care influenza diagnostic tests.** CDC recommends antiviral medications as an adjunct to vaccination, and their potential public health benefit is increased in the context of low VE. A CDC health update issued December 27, 2017, regarding treatment with antiviral medications is available at Clinicians should be aware that influenza activity is widespread, and influenza should be considered as a possible diagnosis in all patients with acute respiratory illness.

The findings in this report are subject to at least four limitations. First, vaccination status included self-report at four of five sites. End-of-season VE estimates based on updated documentation of vaccination status might differ from interim estimates. Second, information from medical records and immunization registries is needed to evaluate VE by vaccine type and for fully vaccinated versus partially vaccinated children, as well as to evaluate the effects of previous season vaccination and timing of vaccination; end-of-season analysis of VE by vaccine type and effects of partial or previous season vaccination is planned. Third, an observational study design has greater potential for confounding and bias relative to randomized clinical trials. However, the test-negative design is widely used in VE studies and has been used by the U.S. Flu VE Network to estimate VE for previous influenza seasons. Finally, small sample sizes in some age groups resulted in wide confidence intervals, and end-of-season VE estimates could change as additional patient data become available or if there is a change in circulating viruses late in the season. It is also important to note that the VE estimates in this report are limited to the prevention of outpatient medical visits rather than more severe illness outcomes, such as hospitalization or death; data from studies measuring VE against more severe outcomes will be available at a later date.

Annual monitoring of VE supports ongoing efforts to improve influenza vaccines. Although more effective vaccines are needed, vaccination prevents a substantial burden of influenza-related illness annually. During the 2014–15 season, when VE against medically attended illness caused by any influenza virus was less than 20%, vaccination was estimated to prevent 11,000–144,000 influenza-associated hospitalizations and 300–4,000 influenza-associated deaths ( Small increases in VE can substantially affect the number of hospitalizations prevented during a severe season (10). Although interim estimates suggest that vaccination has prevented some influenza-related illness this season, influenza vaccines with improved effectiveness are needed to substantially reduce the incidence of disease.
Jennifer K. Meece, Jennifer P. King, Madalyn Palmquist, Lynn Ivacic, Carla Rottscheit, Sarah Kopitzke, Jacklyn Salzwedel, Deanna Cole, Trish Aldrich, Jennifer Anderson, Elizabeth Armagost, Cory Arnold, Marya Theresa Balinghasay, Kaleigh Bettinger Terry Foss, Dyan Friemoth, Wayne Frome, Keith Gilge, Sherri Guzinski, Tara Johnson, Julie Karl, Diane Kohnhorst, Tamara Kronenwetter Koepel, Karen McGreevey, Nidhi Mehta, Vicki Moon, Lisa Ott, Maisie Pettinger, Rebecca Pilsner, DeeAnn Polacek, Martha Presson, Emily Redmond, Megan Sauer, Eleanor Stockheimer, Patrick Stockwell, Sandy Strey, Julie Zierer, Tom Dalcher, Gregg Greenwald, Marshfield Clinic Research Institute, Marshfield, Wisconsin; Joshua G. Petrie, Lois E. Lamerato, Ryan E. Malosh, E.J. McSpadden, Hannah Segaloff, Caroline K. Cheng, Rachel Truscon, Emileigh Johnson, Anne Kaniclides, Elizabeth Alleman, Sarah Bauer, Michelle Groesbeck, Emerson Bouldin, Christoph Baker, Kimberly Berke, Mackenzie Smith, Niharika Rajesh, Kristyn Brundidge, Neha Hafeez, Jayla Jackson, Ian Anastasia, Gabriel Kadoo, University of Michigan, Ann Arbor, and Henry Ford Health System, Detroit, Michigan; G.K. Balasubramani, Todd M. Bear, Heather Eng, Samantha Ford, Edward Garofolo, Robert Hickey, Philip Iozzi, Monika Johnson, Donald B. Middleton, Krissy K. Moehling, Jonathan M. Raviotta, Evelyn C. Reis, Bret Rosenblum, Sean Saul, Theresa Sax, Michael Susick, Joe Suyama, Leonard F. Urbanski, John V. Williams, University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Michael Smith, Chandni Raiyani, Lydia Clipper, Teresa Ponder, Todd Crumbaker, Mary Kylberg, Martha Zayed, Melissa Zdroik, Kimberley Walker, Marcus Volz, Arundhati Rao, Robert Fader, Lea Mallett, Hania Wehbe-Janek, Madhava Beeram, Michael Reis, Jennifer Thomas, Jaime Walkowiak, Jeremy Ray, Renee Day, Deborah Price, Jennifer Fox, Robert Probe, Baylor Scott & White Health, Texas A&M University Health Science Center College of Medicine, Temple, Texas; Erika Kiniry, Stacie Wellwood, C. Hallie Phillips, Suzie Park, Lawrence Madziwa, Matt Nguyen, Kaiser Permanente Washington Health Research Institute, Seattle, Washington; Erin Burns, Rebecca Garten, Thomas Stark, Shoshona Le, Juliana DaSilva, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.

Conflict of Interest
No conflicts of interest were reported.

Wednesday, February 21, 2018

Academy of Laser Dentistry’s Upcoming Annual Meeting Features an Abundance of Dental Team Training


If you are looking to expand your laser skills or if you are a new comer to lasers and are looking to learn as much as possible before using them, the Academy of Laser Dentistry meeting is a great place to be.  Here’s info on what this year’s meeting has to offer:


Coral Springs, FL – February 19, 2018 – The Academy of Laser Dentistry (ALD), is emphasizing a team approach to laser dentistry during ALD 2018, Dentistry’s Laser Meeting. The event is taking place from April 26-28th at the Caribe Royale in Orlando, Florida.

According to ALD’s executive director, Gail Siminovsky, “Laser dentistry delivers better patient outcomes when the entire dental team is well-trained on the many applications, specific techniques and sensible safety procedures related to this technology. That’s why in Orlando, there’s a strong focus on team training.” Here are some examples of ALD 2018’s team-friendly program:

Keynote: “Tongue Tied: A Story Not Silenced by Oral Cancer” presented by Eva Grayzel, Six Step Screening

Roundtable Discussion: “Straight Talk on Diode Lasers: Scientific and Practical Rationale for Clinical Dentistry” moderated by Georgios Romanos, PhD, DDS. Periodontology, Stony Brook University
“The more the dental team knows about laser technology and the business of dentistry, the better the health of your patients and practice, explains Siminovsky, “The ALD supports our valuable auxiliary team members with outstanding presenters and topics.”

Lecture: “What to Say to Get the Pay- Coding, Billing, Scripting,” presented by Karen S. Parker, RDH, BSDH

Lecture: “Laser Use During Implant Care,” presented by Heather Angers, RDH

Lecture: “Photobiomodulation: Applications and Results,” presented by Mary Lynn Smith, RDH, Associate in Applied Science

Lecture: “Non-Surgical Periodontal Treatment Planning,” presented by Mary Lynn Smith, RDH

Workshop: “Give 'Em a Hand: Hygiene Hands-On,” presented by Angie Wallace, RDH and Jeanette Miranda, RDH

Workshop: The Team Approach to Laser Use - Lasers and the Dental Assistant, presented by Angie Wallace, RDH and Jeanette Miranda, RDH

“Today’s successful practice marketing requires the entire dental team to be practice ambassadors on social media, in the office and in the community,” says Siminovsky. “That’s why we’ve included marketing-oriented courses appropriate for the entire team.”

Lecture: “Growing Your Patient Base Through Effective Digital Marketing” presented by Corey Auger, Crystal Clear Digital Marketing

Lecture: “OMG! I Got A Bad Review. What Do I Do?” presented by Leonard Tau, DMD. PCDE

Lecture: “Why Your Staff is Your Most Important Asset” presented by Corey Auger, Crystal Clear Digital Marketing
For detailed and up to date information about ALD 2018, including courses, exhibitors, social events and registration, click here.

About the Academy of Laser Dentistry
The Academy of Laser Dentistry (ALD) is the only independent and unbiased non-profit association devoted to laser dentistry and includes clinicians, academicians and researchers in all laser wavelengths. The Academy is devoted to clinical education, research, and the development of standards and guidelines for the safe and effective use of dental laser technology. ALD was founded in 1993, with the merging of the International Academy of Laser Dentistry, the North American Academy of Laser Dentistry and the American Academy of Laser Dentistry. For more information, visit

About ALD2018:
ALD’s upcoming annual meeting (ALD2018) promises to be the Academy’s biggest annual event to date. This year’s theme is “Innovation, Illumination, Imagination – Celebrating Laser Dentistry 25 Years and Beyond.” ALD2018 will take place from April 26-28th at the Caribe Royale Orlando, Florida. For more information and to register, visit

Tuesday, February 20, 2018

RecordLinc Launches Patient-To-Patient Online Dentist Referral Software I LUV MY DENTIST

RecordLinc Logo.jpg
Today, after months of successful beta testing, RecordLinc, a dental practice management software company, announces the official launch of “I LUV MY DENTIST”, the newest addition to their suite of automation products. This web-based software gives patients a simple way to submit word of mouth referrals using email, texting, and social media platforms. The fully automated system seamlessly integrates with the most popular practice management systems and requires no team training. Once “I LUV MY DENTIST” is installed, it operates on autopilot, inviting top patients to refer friends to dental practices by sharing contact information. “70% of patients say they chose their dentist based on a word of mouth referral and we make it easy to increase word of mouth referrals,” said Travis Rodgers, CEO of RecordLinc.
Another feature of “I LUV MY DENTIST” is the addition of positive testimonials listed directly on the dental office website. “When your existing patients like and trust you, they’re your strongest advocates,” said Rodgers. “To celebrate the launch, we are sharing the ‘LUV’ with our customers.  For a limited time, we’ll waive the startup fee, offer 50% off the monthly service cost, and 100% of the proceeds this week will go to the DonateDentist non-profit.”
More on the Valentine’s Day Offer, visit
To learn more about “I Luv My Dentist” and how it can make it easier for your patients to refer, visit 
Luv My Dentist Logo.png